Clinical Trials
37 trialsAtezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
BCB RIV
Institut du Cancer de Montpellier - Val d'Aurelle
CapTemY90
Abramson Cancer Center at Penn Medicine
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
LUPARPED
Fundación de investigación HM
Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms
Jilin University
NET-COMPARE
British Columbia Cancer Agency
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
PRO-NEM1
Centre Hospitalier Universitaire Dijon
Tumor HI
Rezolute
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
ADJUPANET
Gustave Roussy, Cancer Campus, Grand Paris
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
ELEGANCE
Nantes University Hospital
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
PLANE-PC
University of Michigan Rogel Cancer Center
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
University of Alberta
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Memorial Sloan Kettering Cancer Center
iCaRe2
University of Nebraska
Lumed
University Hospital, Basel, Switzerland
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital
ANTARES
Instituto do Cancer do Estado de São Paulo
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
I-MAT
Melanoma and Skin Cancer Trials Limited
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan
GoTHAM
Melanoma and Skin Cancer Trials Limited
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
University Health Network, Toronto
PRRT
Methodist Health System
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
SUR-CAN
Centre Oscar Lambret
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco